/
Nephrology
Lupus Nephritis
41
Pipeline Programs↗
55
Active Trials↗
40
Companies Involved↗
Lupus Nephritis is a moderately active landscape with 41 programs across 40 companies. The most active players are Roche, AstraZeneca, Novartis. 11 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical15
Phase 15
Phase 210
Phase 311
Approved
No programs
Analysis
Modality Breakdown
76%
Small molecule
25 of 33 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 33 classified programs, each share of the total. Modality classified for 90% of 41 pipeline programs.
Analysis
Trial Status
177
clinical trials
Completed56 · 32%
Recruiting32 · 18%
Terminated30 · 17%
Unknown status24 · 14%
Not yet recruiting14 · 8%
Withdrawn12 · 7%
Other9 · 5%
Clinical Trials
Trial Activity
177 trials
Assessing Residual Inflammation and Macrophage Presence in Lupus Nephritis After 3 Months of Intensified Treatment With Prednisolone, Mycofenolate Mofetil and Voclosporin as Compared to Mycofenolate Mofetil and Prednisolone, an Open Label Randomized Controlled Trial
Recruiting·AAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)·Approved·NCT07760480·55 enrolled
Does The Positive Reno-Protective Effect Of Sodium Glucose Co-Transporter 2 Inhibitors Extend To Lupus Nephritis Population?
Recruiting·—·Approved·NCT07700940·66 enrolled
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)